Agenus Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; comparisons are with the three months ended March 31, 2015 unless otherwise noted. Agenus is an immuno-oncology company developing antibody therapies, cancer vaccines and vaccine adjuvants. Its product candidates remain substantially dependent on clinical development, partners and future financing.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / prior period |
|---|---|---|
| Total revenue | $6.0 million | $4.0 million |
| Research and development expense | $25.0 million | $9.2 million |
| General and administrative expense | $9.2 million | $5.5 million |
| Operating loss | $28.0 million | $18.3 million |
| Net loss | $31.8 million | $18.7 million |
| Net loss attributable to common stockholders per share | $0.37 | $0.28 |
| Net cash used in operating activities | $21.5 million | Net cash provided of $3.3 million |
- Revenue included $4.1 million of Incyte collaboration cost reimbursements, up from $1.8 million, and $1.5 million of deferred revenue amortization, compared with $1.3 million. Service revenue was $147,456; no product gross margin is separately reported.
- R&D expense rose 172%, principally due to higher third-party program costs, increased payroll following the XOMA manufacturing facility acquisition, and share-based compensation. G&A rose 68%, including higher professional fees and share-based compensation.
- Net loss widened partly because net interest expense increased to $4.1 million from $0.4 million following the 2015 subordinated notes and royalty-monetization financing. Q1 2015 also included a $7.5 million contingent purchase price fair-value charge; Q1 2016 recorded a $342,000 fair-value gain.
- Cash, cash equivalents and short-term investments totaled $148.2 million at March 31, down $23.4 million from year-end. Cash and cash equivalents alone were $78.3 million. Current assets were $161.6 million and current liabilities $31.3 million.
- Debt principal, including accrued interest, was reported as $122.0 million; the balance-sheet carrying amount was approximately $118.3 million, including current and long-term portions. The filing reports $14.0 million principal on 2015 Subordinated Notes, due February 2018, and $100.0 million principal under the Note Purchase Agreement.
- Accumulated deficit was $811.0 million; stockholders’ equity was $44.5 million. The company reported no off-balance-sheet arrangements.
Material changes and operating developments
- Agenus commenced a Phase 1 trial of its anti-CTLA-4 antibody after FDA clearance in January 2016. It expected the anti-GITR Phase 1 trial to begin in Q2 2016.
- The company planned to advance Prophage into a randomized, controlled trial for newly diagnosed glioblastoma in the second half of 2016, and anticipated initiating its first AutoSynVax clinical trial within 12 months.
- R&D spending shifted heavily toward antibody programs. Reported Q1 antibody-program costs were $22.5 million, compared with $1.9 million for Prophage.
Outlook, risks and contingencies
- Management said the $148.2 million of cash, cash equivalents and short-term investments was expected to fund current plans through the first half of 2017. The company expects substantial future losses and intends to seek additional funds before cash is depleted; financing may not be available on favorable terms or at all.
- Agenus identified clinical-trial outcomes, regulatory approvals, manufacturing execution, partner performance and access to capital as significant uncertainties. Most antibody programs were early-stage; Prophage trial timing and enrollment were uncertain, and the company did not control some externally sponsored trials.
- Under the Incyte collaboration, Agenus shares costs 50:50 on GITR, OX40 and two additional programs. Costs could be substantial and program decisions are jointly managed.
- The $100 million royalty-backed notes accrue interest at 13.5% annually, compounded quarterly, and are repayable from specified GSK shingles and malaria vaccine royalties. Those royalties are directed to note obligations. Agenus guarantees specified payment obligations; put, make-whole or default payments could materially harm liquidity. Repayment also depends on GSK product approval and commercial sales.
- Key risks include dependence on collaborators and licensees, possible clinical or regulatory failure, manufacturing and supply constraints, competition, intellectual-property disputes, foreign-currency exposure and dilution from potential share issuance. The filing notes that Janssen terminated its QS-21 license.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter. No specific financial guidance beyond the stated cash runway was provided.
Important facts for investors to verify
- Whether operating cash use and R&D spending remain consistent with the stated runway through the first half of 2017, and the timing and terms of any additional financing.
- Progress and costs for the anti-CTLA-4, anti-GITR, Prophage and AutoSynVax programs, including trial starts, enrollment and results.
- GSK’s regulatory and commercial progress on its shingles and malaria vaccines, and the resulting capacity of royalties to service the 13.5% notes and any contingent guarantee obligations.
- Reconciliation of the reported $122.0 million debt principal including accrued interest with the approximately $118.3 million balance-sheet carrying value, and the terms and triggers of contingent obligations.
- Potential dilution from the shelf and at-the-market programs, outstanding options and warrants, preferred stock conversion, and acquisition-related milestone or share obligations.